NUTEX InvestmentsBUD:NUTEX -5.22%52 PS Ratio is 4,233.33 as of Jul. 09, 2026, which is 28% above its 10-year median of 3,305.00. GuruFocus rates BUD:NUTEX with a GF Score™ of 52/100 and a GF Value™ of Ft13.80 (Fairly Valued). The stock has 3 warning signs investors should review. Among 952 Drug Manufacturers companies, NUTEX Investments ranks worse than 99.89% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, NUTEX Investments's share price is Ft12.70.
NUTEX Investments's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was Ft0.00. Hence, NUTEX Investments's PS Ratio for today is 4,233.33.
Good Sign:
NUTEX Investments PLC stock PS Ratio (=4233.33) is close to 2-year low of 4233.33.
The historical rank and industry rank for NUTEX Investments's PS Ratio or its related term are showing as below:
BUD:NUTEX'
s PS Ratio Range Over the Past 10 Years
Min: 1.91 Med: 3305 Max: 8200
Current: 4233.33
During the past 13 years, NUTEX Investments's highest PS Ratio was 8200.00. The lowest was 1.91. And the median was 3305.00.
BUD:NUTEX's PS Ratio is ranked worse than 99.89% of 952
companies
in the Drug Manufacturers industry
Industry Median: 2.265
vs BUD:NUTEX: 4233.33
NUTEX Investments PLC revenue per share has been in decline for the last 5 years.
During the past 5 years, the average Revenue per Share Growth Rate was -9.40% per year.
During the past 10 years, the average Revenue per Share Growth Rate was -59.80% per year.
During the past 13 years, NUTEX Investments's highest 3-Year average Revenue per Share Growth Rate was 6.70% per year. The lowest was -90.00% per year. And the median was -51.15% per year.
Back to Basics: PS Ratio
NUTEX Investments (BUD:NUTEX) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
NUTEX Investments PS Ratio Related Terms
NUTEX Investments PS Ratio Historical Data
* Premium members only.
The historical data trend for NUTEX Investments's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, NUTEX Investments's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NUTEX Investments PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, NUTEX Investments's PS Ratio distribution charts can be found below:
* The bar in red indicates where NUTEX Investments's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
NUTEX Investments's Share Price of today is Ft12.70.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. NUTEX Investments's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was Ft0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
NUTEX Investments (BUD:NUTEX) has a PS Ratio of 4,233.33 as of Jul. 09, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on NUTEX Investments and its competitors. This is 28% above median its historical median of 3,305.00. Over the past decade, NUTEX Investments' PS Ratio has ranged from 1.91 to 8,200.00. According to the industry distribution chart, NUTEX Investments ranks #951 out of 952 companies in the Drug Manufacturers industry, placing it in the top 99.9%.
Is NUTEX Investments' PS Ratio too high?
NUTEX Investments' current PS Ratio of 4,233.33 is 28% above median its 10-year median of 3,305.00. Over the past 10 years, this metric has ranged from a low of 1.91 to a high of 8,200.00. The Drug Manufacturers industry median PS Ratio is 2.27. NUTEX Investments' value of 4,233.33 is 186802% above this industry median. Based on the distribution chart, NUTEX Investments ranks #951 out of 952 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, NUTEX Investments has a GF Score™ of 52/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does NUTEX Investments' PS Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, NUTEX Investments ranks #951 out of 952 companies for PS Ratio. This places NUTEX Investments in the lower half of its industry. The industry median PS Ratio is 2.27. NUTEX Investments' value of 4,233.33 is 186802% above this benchmark. Historically, NUTEX Investments' own PS Ratio has ranged from 1.91 to 8,200.00 over the past decade. While the company's 10-year median is 3,305.00 vs. the industry median of 2.27, NUTEX Investments has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.27, based on 952 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NUTEX Investments's current PS Ratio of 4,233.33 is 186802% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on NUTEX Investments and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NUTEX Investments's current PS Ratio is 4,233.33, which is 28% above median its own 10-year median of 3,305.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NUTEX Investments stock overvalued right now?
Based on GuruFocus' analysis, NUTEX Investments (BUD:NUTEX) is currently considered Fairly Valued. The stock's GF Value™ is Ft13.80, compared to a current price of Ft12.70 — trading 8% below its estimated fair value. The current PS Ratio is 4,233.33, which is 28% above median its 10-year median of 3,305.00 and 186802% above the Drug Manufacturers industry median of 2.27. NUTEX Investments' overall GF Score™ is 52/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For NUTEX Investments (BUD:NUTEX), the current PS Ratio is 4,233.33 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NUTEX Investments (BUD:NUTEX) Overvalued in 2026?
Based on GuruFocus' analysis, NUTEX Investments stock appears to be undervalued.
The current stock price of Ft12.70 is trading 8% below its estimated GF Value™ of Ft13.80.
GuruFocus considers NUTEX Investments to be Fairly Valued.
Key valuation signals for BUD:NUTEX:
PS Ratio: 4,233.33 (28% above median its 10-year median of 3,305.00)
GF Value™: Ft13.80 vs. price of Ft12.70 (8% below fair value)
Industry Position: 186802% above the Drug Manufacturers median (#951 of 952)
No single metric tells the full story. See the BUD:NUTEX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NUTEX Investments PLC operates as a drug manufacturer in Hungary. The company is engaged in production of products that focuses on health, vitality, and natural ingredients.
52GF Score
Get the complete analysis for BUD:NUTEX
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BUD:NUTEX has been successfully added to your 
